LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

Saved in:
Bibliographic Details
Title: LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
Authors: Mileshkin, L.1 (AUTHOR), Bochtler, T.2 (AUTHOR), Pauli, C.3 (AUTHOR), Durán-Pacheco, G.4 (AUTHOR), Arslan, C.5 (AUTHOR), Bigot, F.6 (AUTHOR), Chalabi, N.7 (AUTHOR), Cook, N.8 (AUTHOR), Italiano, A.9 (AUTHOR), Losa, F.10 (AUTHOR), Menezes, J.11 (AUTHOR), Michaud, C.7 (AUTHOR), Ozguroglu, M.12 (AUTHOR), Pazo Cid, R.A.13 (AUTHOR), Ross, J.S.14 (AUTHOR), Shiu, K-K.15 (AUTHOR), Stahl, M.16 (AUTHOR), Thomas, M.17 (AUTHOR), Moch, H.3 (AUTHOR), Krämer, A.18 (AUTHOR)
Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS1254-S1255. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2023.10.006